Biogen Inc.
The brokerage presently has a $338.00 price target on the biotechnology company's stock. Goldman Sachs Group, Inc. 's price objective points to a potential upside of 19.96% from the company's previous close.
from Biotech News
The brokerage presently has a $338.00 price target on the biotechnology company's stock. Goldman Sachs Group, Inc. 's price objective points to a potential upside of 19.96% from the company's previous close.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments